Donald Woytowitz

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Clinical Oncology · 2010 · 447 citations

Results Median Pfs-irrc, Medicine, Cancer Management +12

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 167 citations · Full text

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Thoracic Oncology · 2007 · 84 citations · Full text

Medicine, Pathology, Taxane/carboplatin Versus Taxane/carboplatin +6

Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss

James R. Berenson, Ori Yellin, Ralph V. Boccia et al. · Clinical Cancer Research · 2008 · 70 citations

Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network

Jeffrey Patton, David R. Spigel, F. Anthony Greco et al. · Journal of Clinical Oncology · 2006 · 32 citations

Maintenance Bevacizumab, Phase Ii Trial, Medicine +15